Thermoacoustic Method for Estimating Liver Fat Fraction
Condition(s) studied
Investigational drug(s) / intervention(s)
Thermoacoustic Enhanced Ultrasound: a novel Thermoacoustic Enhanced imaging device
Study summary
The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements. Participants will have a scan with our device, then they will go have an abdominal MRI completed. The goal is to create a more accessible device to measure liver fat as it is an indicator for overall health and metabolic diseases.
Eligibility
Primary outcome measure(s)
- Correlation between Thermoacoustic Fat Fraction (TAFF) and the MRI-PDFF — From enrollment until the statistical analysis is reviewed, typically 2 weeks after last MRI data is received.
The correlation between TAFF and the MRI-PDFF, will be conducted using the calculation of the cumulative distribution of the correlation coefficient as derived by Guenther
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| ENDRA Life Sciences | Ann Arbor | Michigan | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07321925 on ClinicalTrials.gov ↗ ← All trials in the USA